학술논문
Therapy-related myeloid neoplasms after treatment for ovarian cancer: A retrospective single-center case series.
Document Type
Academic Journal
Author
Matsuoka A; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.; Tate S; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.; Nishikimi K; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.; Otsuka S; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.; Usui H; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.; Tajima S; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.; Habu Y; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.; Nakamura N; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.; Okuya R; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.; Katayama E; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.; Shozu M; Evolution and Reproductive Medicine, Medical Mycology Research Center, Chiba University, Chiba, Japan.; Inaba Y; Biostatistics Section, Clinical Research Center, Chiba University, Chiba, Japan.; Koga K; Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba University, Chiba, Japan.
Source
Publisher: Wiley on behalf of the Japan Society of Obstetrics and Gynecology] Country of Publication: Australia NLM ID: 9612761 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1447-0756 (Electronic) Linking ISSN: 13418076 NLM ISO Abbreviation: J Obstet Gynaecol Res Subsets: MEDLINE
Subject
Language
English
Abstract
Objective: Therapy-related myeloid neoplasms (t-MNs) are often fatal and arise as late complications of previous anticancer drug treatment. No single-center case series has examined t-MNs in epithelial ovarian cancer (EOC).
Methods: All patients with EOC treated at Chiba University Hospital between 2000 and 2021 were included. We retrospectively analyzed the characteristics, clinical course, and outcomes of patients who developed t-MNs.
Results: Among 895 cases with EOC, 814 cases were treated with anticancer drugs. The median follow-up period was 45 months (interquartile range, 27-81) months. Ten patients (1.2%) developed t-MNs (FIGO IIIA in one case, IIIC in three, IVA in one, and IVB in five). Nine patients were diagnosed with myelodysplastic syndrome and one with acute leukemia. One patient with myelodysplastic syndrome developed acute leukemia. The median time from the first chemotherapy administration to t-MN onset was 42 months (range, 21-94 months), with t-MN diagnoses resulting from pancytopenia in four cases, thrombocytopenia in three, and blast or abnormal cell morphology in four. The median number of previous treatment regimens was four (range, 1-7). Paclitaxel + carboplatin therapy was administered to all patients, gemcitabine and irinotecan combination therapy to nine, bevacizumab to eight, and olaparib to four. Six patients received chemotherapy for t-MN. All patients died (eight cancer-related deaths and two t-MN-related deaths). None of the patients was able to restart cancer treatment. The median survival time from t-MN onset was 4 months.
Conclusions: Patients with EOC who developed t-MN were unable to restart cancer treatment and had a significantly worse prognosis.
(© 2024 Japan Society of Obstetrics and Gynecology.)
Methods: All patients with EOC treated at Chiba University Hospital between 2000 and 2021 were included. We retrospectively analyzed the characteristics, clinical course, and outcomes of patients who developed t-MNs.
Results: Among 895 cases with EOC, 814 cases were treated with anticancer drugs. The median follow-up period was 45 months (interquartile range, 27-81) months. Ten patients (1.2%) developed t-MNs (FIGO IIIA in one case, IIIC in three, IVA in one, and IVB in five). Nine patients were diagnosed with myelodysplastic syndrome and one with acute leukemia. One patient with myelodysplastic syndrome developed acute leukemia. The median time from the first chemotherapy administration to t-MN onset was 42 months (range, 21-94 months), with t-MN diagnoses resulting from pancytopenia in four cases, thrombocytopenia in three, and blast or abnormal cell morphology in four. The median number of previous treatment regimens was four (range, 1-7). Paclitaxel + carboplatin therapy was administered to all patients, gemcitabine and irinotecan combination therapy to nine, bevacizumab to eight, and olaparib to four. Six patients received chemotherapy for t-MN. All patients died (eight cancer-related deaths and two t-MN-related deaths). None of the patients was able to restart cancer treatment. The median survival time from t-MN onset was 4 months.
Conclusions: Patients with EOC who developed t-MN were unable to restart cancer treatment and had a significantly worse prognosis.
(© 2024 Japan Society of Obstetrics and Gynecology.)